MarketCap
Facebook
X
TelegramAnnual report 2021
added 12-23-2023
Burning Rock Biotech Limited Revenue 2011-2026 | BNR
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Burning Rock Biotech Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 508 M | 430 M | 382 M | 209 M | 111 M | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 508 M | 111 M | 328 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
6.32 B | $ 119.98 | 0.83 % | $ 36.5 B |  USA |
 |
Anixa Biosciences
ANIX
|
210 K | $ 2.93 | 3.53 % | $ 95.1 K | USA |
 |
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Aspira Women's Health
AWH
|
8.18 M | - | -6.19 % | $ 10.5 M | USA |
|
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Castle Biosciences
CSTL
|
332 M | $ 27.88 | 1.12 % | $ 774 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M |  Britain |
 |
Heska Corporation
HSKA
|
257 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
6.37 M | - | -20.0 % | $ 1.06 M | USA |
 |
Charles River Laboratories International
CRL
|
4.02 B | $ 177.64 | 1.03 % | $ 8.8 B | USA |
 |
Fulgent Genetics
FLGT
|
283 M | $ 13.72 | -0.54 % | $ 415 M | USA |
 |
Accelerate Diagnostics
AXDX
|
2.97 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
6.79 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
651 M | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
3.18 B | - | - | $ 10.7 B | USA |
 |
Motus GI Holdings
MOTS
|
319 K | - | -34.28 % | $ 263 K |  Israel |
|
Biodesix
BDSX
|
71.3 M | $ 15.46 | -0.26 % | $ 2 B | USA |
 |
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
122 M | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
30.8 M | $ 1.12 | - | $ 1.42 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
11 B | $ 208.13 | -0.11 % | $ 23.1 B | USA |
 |
Danaher Corporation
DHR
|
24.6 B | $ 204.09 | 0.02 % | $ 145 B | USA |
 |
Organovo Holdings
ONVO
|
144 K | - | -2.3 % | $ 19.4 M | USA |
 |
Exact Sciences Corporation
EXAS
|
3.25 B | $ 103.35 | -0.02 % | $ 19.5 B | USA |
 |
Bioventus
BVS
|
512 M | $ 8.62 | -1.37 % | $ 540 M | USA |
 |
DarioHealth Corp.
DRIO
|
20.4 M | $ 10.3 | - | $ 292 M | Israel |
 |
DexCom
DXCM
|
4.66 B | $ 71.8 | -1.75 % | $ 28 B | USA |
 |
PerkinElmer
PKI
|
2.86 B | - | -0.91 % | $ 14.7 B | USA |
 |
Psychemedics Corporation
PMD
|
22.1 M | - | -1.84 % | $ 15.3 M | USA |
 |
IDEXX Laboratories
IDXX
|
4.3 B | $ 632.85 | -0.42 % | $ 50.9 B | USA |
 |
Illumina
ILMN
|
4.37 B | $ 130.71 | 0.89 % | $ 20.8 B | USA |
 |
QIAGEN N.V.
QGEN
|
2.25 B | - | - | $ 10.6 B |  Niderland |
 |
Quotient Limited
QTNT
|
43.4 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
ICON Public Limited Company
ICLR
|
5.48 B | $ 108.37 | -0.3 % | $ 8.94 B |  Irlanda |
 |
Renalytix AI plc
RNLX
|
2.29 M | - | 5.66 % | $ 22.7 M | Britain |
 |
CareDx, Inc
CDNA
|
380 M | $ 18.76 | -0.21 % | $ 1 B | USA |
 |
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
Guardant Health
GH
|
982 M | $ 93.57 | 0.28 % | $ 11.7 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
14 B | $ 281.62 | -0.51 % | $ 23.4 B | USA |
 |
Lantheus Holdings
LNTH
|
1.54 B | $ 78.82 | -0.03 % | $ 5.32 B | USA |
 |
IQVIA Holdings
IQV
|
16.3 B | $ 175.43 | 0.82 % | $ 30.2 B | USA |
 |
Brainsway Ltd.
BWAY
|
41 M | $ 12.09 | 4.27 % | $ 99.4 M | Israel |
 |
Co-Diagnostics
CODX
|
6.81 M | - | - | $ 79.8 M | USA |
 |
Mettler-Toledo International
MTD
|
4.03 B | $ 1 316.93 | 0.07 % | $ 27.1 B | Schweiz |
 |
Myriad Genetics
MYGN
|
824 M | $ 5.32 | 0.47 % | $ 493 M | USA |